Neurocrine Biosciences
NBIX
#1454
Rank
S$15.98 B
Marketcap
$157.86
Share price
-4.21%
Change (1 day)
4.11%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - P/B ratio

P/B ratio as of November 2024 : 4.41

According to Neurocrine Biosciences 's latest financial reports the company has a price-to-book ratio of 5.34811.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Neurocrine Biosciences - P/B ratio (from 2001 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-31N/A-100%
2023-12-315.80-13.73%
2022-12-316.7214.33%
2021-12-315.88-26.05%
2020-12-317.95-48.94%
2019-12-3115.615.47%
2018-12-3113.5-26.91%
2017-12-3118.572.81%
2016-12-3110.7-7.13%
2015-12-3111.540.46%
2014-12-318.1956.68%
2013-12-315.2262.26%
2012-12-313.22-58.81%
2011-12-317.82-63.93%
2010-12-3121.7-28.38%
2009-12-3130.3801%
2008-12-313.36129.43%
2007-12-311.4616.64%
2006-12-311.26-78.98%
2005-12-315.9730.56%
2004-12-314.57-7.13%
2003-12-314.92-21.13%
2002-12-316.24

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
3.55-19.47%๐Ÿ‡บ๐Ÿ‡ธ USA
1.48-66.41%๐Ÿ‡ฌ๐Ÿ‡ง UK
-171-3,978.40%๐Ÿ‡บ๐Ÿ‡ธ USA
49.8 1,028.39%๐Ÿ‡บ๐Ÿ‡ธ USA
48.5 998.90%๐Ÿ‡บ๐Ÿ‡ธ USA
1.52-65.53%๐Ÿ‡บ๐Ÿ‡ธ USA
2.51-43.19%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0229-100.52%๐Ÿ‡บ๐Ÿ‡ธ USA